Program
QLS-111
A development code. Also written as “QLS-111 Ophthalmic Solution (0.015%)”, “QLS-111 Ophthalmic Solution (0.075%)” and “QLS-111-FDC”.
Its studies are mostly in Glaucoma, Open-Angle · Low Tension Glaucoma, led by Qlaris Bio.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qlaris Bio | 50 open or running | phase 3since Jan 17, 2026 | Aug 18, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 18, 2023First studies: 2 phase 2 studiesFirst studyNCT06030193, NCT06016972
- Jan 31, 2024Phase 2 study in Glaucoma, Open-AngleNCT06249152 · 36 enrolled · United States
- Dec 22, 2025Phase 2 study in Glaucoma, Open-AngleNCT07354477 · 9 enrolled · United States
- Jan 17, 2026Phase 3 study in Glaucoma, Open-AnglePhase 3 reachedNCT07354516 · 64 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07354516Glaucoma, Open-Angle · United States | 3 | Completed | Jul 22, 2026 | 64 |
| NCT07354477Glaucoma, Open-Angle · United States | 2 | Completed | Oct 1, 2026 | 9 |
| NCT06249152Glaucoma, Open-Angle · United States | 2 | Completed | Dec 20, 2024 | 36 |
| NCT06030193Low Tension Glaucoma · South Korea | 2 | Completed | Feb 23, 2026 | 37 |
| NCT06016972Glaucoma, Open-Angle · United States | 2 | Completed | Aug 20, 2024 | 63 |
How it is read
Names in the registry
- “QLS-111 Ophthalmic Solution (0.015%)”, 1 entry
- “QLS-111 Ophthalmic Solution (0.075%)”, 1 entry
- “QLS-111-FDC”, 1 entry
- “QLS-111 ophthalmic solution (0.015%)”, 1 entry
- “Experimental: QLS-111 ophthalmic solution, (0.015%)”, 1 entry
Codes read as this program: QLS111.
Conditions, from the studies’ own filings
- Glaucoma, Open-Angle, 4 studies
- Low Tension Glaucoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.